Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 998 participants.
Also called NCT02476006
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 998 participants
- Sponsor
- Registry
-
NCT02476006 -
2015-000620-28
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Poland, Romania, Slovakia, Slovenia, Spain, Switzerland
- Registry status
- Completed
Technical summary
Registry record NCT02476006. Allocation not applicable; no masking; primary purpose treatment. Start 2015-06-23 (actual); primary completion 2019-04-12 (actual). Results posted on 2020-03-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- ALIROCUMAB SAR236553 (REGN727)
- Intervention (Drug)
- placebo (for injection training only)
- Intervention (Drug)
- ezetimibe
- Intervention (Drug)
- atorvastatin
- Intervention (Drug)
- rosuvastatin
- Intervention (Drug)
- simvastatin
- Lead sponsor
- Sanofi
- Collaborator
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct02476006- Content hash
8d2320ee061b89a1434ac5b410748c9482d99e4536c7789fe55697dd4b2e54e9